Pharma's Market
SPECIAL REPORT
MOST SHARED
- Zero China Growth Is ‘Probable’: Gordon Chang
- Spain to Inject 19 Billion Euros into Bankia
- Marc Faber: 100% Chance of Global Recession
- Beijing Faces Brussels Action on Telecoms Aid
- Citigroup Lost $20 Million on Facebook IPO Trades
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- China Growth Risks Signal Need for Fiscal Action
- Senate Summons Dimon to 'Get to the Bottom' of JPM Mess
- Romney Leads Poll Of Small Business Owners
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain to Inject Emergency 19 Billion Euros into Bankia
- EU Set to Launch Action Against China Over Telecom Aid
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Marc Faber: Chance of Global Recession Is Now 100%
- Cool Jobs: From Gold Stacker to Bed Tester
- 'Flash Sale' Sites: Gimmick, or Online Shopping Future?
RSS FEED
Wyeth and Elan Face Big Test
Text Size 
Reporter
 |
AP Wyeth |
We just finished back-to-back coverage of the world's largest oncology and diabetes conferences. Now we get a bit of a break before shifting our attention to Alzheimer's.
Specifically, analysts say Wyeth [WYE
Loading...
()
]and Elan[ELN
Loading...
()
] could be out with basic results on a mid-stage test for their drug by the end of this month.
Then they're expected to present the detailed data at the International Conference on Alzheimer's Disease in late July. Some analysts think if the drug shows promise it could become the biggest selling drug in history.
Bill Tanner at Leerink Swann writes in a research note to clients today that "investors should not expect to see significant treatment effects given the relatively small size of the trial and the heterogeneity of the patients population." (Dear Elanians: I'm just reporting what the man said, please do not flood my inbox with complaints about what you might see as his bearish analysis.)
Nonetheless, he believes there will probably be enough positive data for the companies to continue to move forward. Coincidentally, Brian McCarthy, a biotech analyst at Merriman Curhan Ford initiated coverage today of ELN with a Buy rating.
But he agrees with Tanner about the pending test results. "We believe a statistically significant response in Phase 2 (mid-stage clinical trial) is unlikely given the small number of patients," McCarthy writes.
He justifies his Buy rating by saying, "Positive Phase 2 Alzheimer's data could add approximately $7 in the near-term, or approximately $15 longer term if (the drug) succeeds for AD."
But buyer beware. Both analysts also say that ELN shares could be volatile in the coming weeks.
Leerink Swann may trade ELN shares. Typically, if a company doesn't have any disclosures on a stock I won't mention it. I only point them out if they exist. But since MCF is initiating coverage today I will say it has none to make.
An estimates five million Americans have Alzheimer's. That number is expected to multiply.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
